Lapatinib
- Generic Name
- Lapatinib
- Brand Names
- Tykerb, Tyverb
- Drug Type
- Small Molecule
- Chemical Formula
- C29H26ClFN4O4S
- CAS Number
- 231277-92-2
- Unique Ingredient Identifier
- 0VUA21238F
- Background
Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epidermal growth factor receptor type 2 (HER2...
- Indication
Indicated in combination with capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress the human epidermal receptor type 2 (HER2) protein and who have received prior therapy including an anthracycline, a taxane, and trastuzumab.
- Associated Conditions
- Metastatic Breast Cancer, Refractory, advanced Breast cancer, Refractory, metastatic Breast cancer
- Associated Therapies
- -
TRYHARD: Radiation Therapy Plus Cisplatin With or Without Lapatinib in Treating Patients With Head and Neck Cancer.
- Conditions
- Interventions
- First Posted Date
- 2012-10-22
- Last Posted Date
- 2023-10-17
- Lead Sponsor
- Radiation Therapy Oncology Group
- Target Recruit Count
- 142
- Registration Number
- NCT01711658
- Locations
- 🇺🇸
University of California, San Diego, La Jolla, California, United States
🇺🇸Sutter General Hospital, Sacramento, California, United States
🇨🇦McGill Cancer Centre at McGill University, Montreal, Quebec, Canada
Single-center Investigator Initiated Pilot Study Investigating the Tumor Response of Squamous Cell Carcinoma Lesions in Patients Under Lapatinib Treatment
- First Posted Date
- 2012-08-16
- Last Posted Date
- 2014-12-03
- Lead Sponsor
- University of Zurich
- Target Recruit Count
- 10
- Registration Number
- NCT01666431
- Locations
- 🇨🇭
University Hospital Zurich, Division of Dermatology, Zurich, ZH, Switzerland
ErbB2 Positive Metastatic Breast Cancer
- First Posted Date
- 2012-08-07
- Last Posted Date
- 2013-02-27
- Lead Sponsor
- China Medical University Hospital
- Target Recruit Count
- 15
- Registration Number
- NCT01658358
- Locations
- 🇨🇳
China Medical University Hospital, Taichung, Taiwan
Determination of Intratumoral Concentrations of Kinase Inhibitors in Patients With Advanced Solid Malignancies.
- First Posted Date
- 2012-07-10
- Last Posted Date
- 2021-04-15
- Lead Sponsor
- Amsterdam UMC, location VUmc
- Target Recruit Count
- 43
- Registration Number
- NCT01636908
- Locations
- 🇳🇱
VUMedical Center, Amsterdam, Netherlands
Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery
- First Posted Date
- 2012-06-05
- Last Posted Date
- 2023-09-15
- Lead Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT01612351
- Locations
- 🇺🇸
The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
A Randomized Study of TH Versus THL in First Line Treatment of HER2-positive Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-02-03
- Last Posted Date
- 2023-04-06
- Lead Sponsor
- Cancer Trials Ireland
- Target Recruit Count
- 75
- Registration Number
- NCT01526369
- Locations
- 🇫🇮
Helsinki University Hopsital, Helsinki, Finland
🇪🇸Hospital Nuestra Senora de Sonsoles, Avila, Spain
🇪🇸Hospital Clinico Universitario 'Lozano Blesa', Zaragoza, Spain
Letrozole and Lapatinib Followed by Everolimus in Women With Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2011-12-26
- Last Posted Date
- 2022-02-11
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 7
- Registration Number
- NCT01499160
- Locations
- 🇺🇸
University of Maryland Marlene & Stewart Greenebaum Cancer Center, Baltimore, Maryland, United States
Modulation of Response to Hormonal Therapy With Lapatinib and/or Metformin in Patients With Metastatic Breast Cancer
- First Posted Date
- 2011-11-22
- Last Posted Date
- 2014-02-20
- Lead Sponsor
- Fondazione Michelangelo
- Target Recruit Count
- 32
- Registration Number
- NCT01477060
- Locations
- 🇮🇹
Cliniche Gavazzeni S.p.A. - Humanitas Gavazzeni, Bergamo, BG, Italy
🇮🇹Fondazione Poliambulanza, Brescia, BS, Italy
🇮🇹Azienda Ospedaliera San Gerardo, Monza, MB, Italy
Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2011-10-19
- Last Posted Date
- 2016-04-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 43
- Registration Number
- NCT01454804
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Randomized RT +/- Lapatinib for Advanced Solid Tumor Cancer Patients Receiving Radiation Therapy for Metastatic Disease
- Conditions
- Interventions
- First Posted Date
- 2011-09-01
- Last Posted Date
- 2015-07-08
- Lead Sponsor
- Virginia Commonwealth University
- Target Recruit Count
- 6
- Registration Number
- NCT01427322
- Locations
- 🇺🇸
Hunter Holmes McGuire VA Medical Center, Richmond, Virginia, United States
🇺🇸Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.